ArriVent BioPharma/$AVBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
$AVBP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
52
Website
AVBP Metrics
BasicAdvanced
$713M
-
-$3.78
-
-
Price and volume
Market cap
$713M
52-week high
$34.51
52-week low
$15.47
Average daily volume
375K
Financial strength
Current ratio
14.343
Quick ratio
13.633
Total debt to equity
0.068
Profitability
Management effectiveness
Return on assets (TTM)
-23.10%
Return on equity (TTM)
-49.00%
Valuation
Price to book
3.28
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
-5.495
Free cash flow yield (TTM)
-18.20%
Free cash flow per share (TTM)
-3.551
Growth
Earnings per share change (TTM)
-59.00%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
Bulls say / Bears say
ArriVent BioPharma's lead candidate, firmonertinib, demonstrated a median progression-free survival of 16.0 months in first-line NSCLC patients with EGFR PACC mutations, indicating strong efficacy. (globenewswire.com)
The company successfully completed a $75 million public offering in July 2025, bolstering its financial position to support ongoing and future clinical programs. (globenewswire.com)
Analysts have a consensus 'Strong Buy' rating for AVBP, with a 12-month price target of $39.00, suggesting significant upside potential. (stockanalysis.com)
ArriVent reported a net loss of $64.4 million for Q1 2025, reflecting high operational expenses and ongoing financial challenges. (marketchameleon.com)
The company's stock price has experienced volatility, with a 52-week range between $15.47 and $36.37, indicating potential instability. (stockanalysis.com)
Despite positive clinical data, firmonertinib is still in clinical trials, and any delays or unfavorable results could negatively impact the company's prospects. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
AVBP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $713M as of August 01, 2025.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of August 01, 2025.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.